



## Clinical trial results:

### Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210).

#### Summary

EudraCT number	2010-019575-29
Trial protocol	GB
Global end of trial date	07 April 2017

#### Results information

Result version number	v1
This version publication date	27 July 2018
First version publication date	27 July 2018
Summary attachment (see zip file)	CLL210 Final Study Report (resubmitted CLL210_Final Clinical Trial Report.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	CLL210 Version 10.1
-----------------------	---------------------

##### Additional study identifiers

ISRCTN number	ISRCTN40303610
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	University of Liverpool
Sponsor organisation address	Brownlow Street, Liverpool, United Kingdom, L69 3GL
Public contact	Michael Stackpoole, Liverpool Cancer Trials Unit, 0151 795 7321, mstack@liverpool.ac.uk
Scientific contact	Dr Mel Oates, Molecular and Clinical Cancer Medicine, 0151 706 4845, melly@liv.ac.uk
Sponsor organisation name	Royal Liverpool and Broadgreen University Hospitals NHS Trust
Sponsor organisation address	Prescot Street, Liverpool, United Kingdom, L7 8XP
Public contact	Michael Stackpoole, Liverpool Clinical Trials Unit, 0151 7957321, mstack@liverpool.ac.uk
Scientific contact	Dr Mel Oates, Molecular and Clinical Cancer Medicine, 0151 7064845, melly@liv.ac.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 June 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 April 2017
Global end of trial reached?	Yes
Global end of trial date	07 April 2017
Was the trial ended prematurely?	No

Notes:

---

## General information about the trial

Main objective of the trial:

To investigate the safety and efficacy of combination induction therapy with ofatumumab, dexamethasone and lenalidomide in patients with high-risk CLL.

Primary:

- CR\CRi and tolerance rate (absence of Grade 3+ infection and no treatment related death) after 6m induction therapy.

Secondary:

- Overall, complete and partial response rates following induction therapy
- Minimal residual disease negativity rate following induction therapy
- Overall survival (from start of study treatment to death)
- PFS (from initiation of study treatment to progression or death)
- Time to treatment failure (from initiation of study treatment to treatment failure defined as progression, death or initiation of alternative treatment due to failure to achieve CR or PR)
- Duration of response (from first achievement of CR or PR to first time of progression or death)
- Toxicity
- Quality of life
- Descriptive summary of PFS and overall survival among transplant-eligible patients

---

Protection of trial subjects:

Central and on-site monitoring was conducted to help protect patients and to monitor performance relating to trial procedures, trial intervention administration and laboratory/data collection processes. A risk assessment was carried out to determine the level of monitoring required, and subsequently a monitoring plan was developed to document how and when monitoring is conducted and to what extent. Patient safety was also monitored via LCTU pharmacovigilance procedures (reporting and review of adverse event data) and by an ISDMC.

A Trial Management Group regularly reviewed central monitoring reports and advised accordingly.

Following completion of study treatment, routine follow-up assessments were planned every 2 months until disease progression, second-line induction therapy initiated, or until 12 months after the last patient recruited into the study completed induction treatment, whichever was earliest.

Serious adverse events were followed-up until resolution or death.

Annual safety reports were submitted to the national regulatory authorities.

---

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 February 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	6 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 64
Worldwide total number of subjects	64
EEA total number of subjects	64

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	26
From 65 to 84 years	37
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

The CLL210 trial recruited 64 NHS patients from 19 centres across England, Scotland and Wales between 23/01/2012 and 31/10/2015.

### Pre-assignment

Screening details:

64 of the 92 patients screened were recruited to the study. Patients provided consent and then a series of screening assessments were performed to determine eligibility, within 42 days prior to the first study treatment.

### Period 1

Period 1 title	Baseline
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Baseline
-----------	----------

Arm description:

Single arm study followed by randomisation to maintenance treatment/no maintenance treatment for responders.

- Initially the induction treatment regimen included Alemtuzumab instead of Ofatumumab and a subsequent randomisation to lenalidomide maintenance or no further treatment for eligible patients (2 years follow-up). The study was planned to recruit 85 patients but only 16 were recruited before Alemtuzumab was withdrawn. All 16 patients received treatment and were followed-up as per protocol.
- Alemtuzumab was replaced by Ofatumumab; the study was re-initiated with the same design, statistical considerations and recruitment target; 85 more patients were planned to be recruited.
- Recruitment target was reduced to 50 patients resulting in new statistical considerations (increased type I error rate).
- Randomised part of the study was dropped due to very few patients being eligible and follow-up reduced to one instead of two years. This affected only the last two patients.

Arm type	Experimental
Investigational medicinal product name	Alemtuzumab
Investigational medicinal product code	ATC Code: L04AA34
Other name	Campath, MabCampath, Lemtrada
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Prior to its withdrawal, alemtuzumab was sourced commercially by each study centre. Alemtuzumab was administered intravenously in clinic to patients being monitored by research staff.

Alemtuzumab 30mg sc, three times a week, weeks 7-22

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Dexamethasone was sourced commercially by each study centre, biosimilar products were permitted and could be labelled and stored according to local practice.

Dexamethasone 40mg, po, od, days 1-4, weeks 1, 3, 5, 7, 9, 11, 13, 15

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	ATC Code: L04AX04
Other name	Revlimid
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

Lenalidomide was provided free by Celgene for the CLL210 trial in the form of hard capsules of Revlimid; 5mg and 10mg capsules with an excipient of 147mg and 294mg of anhydrous lactose respectively. Stock was ordered from Celgene, via the LCTU using controlled documentation, and delivered direct to site.

Lenalidomide 5mg, od (weeks 3-4), 10mg od (weeks 5-24)

Investigational medicinal product name	Ofatumumab
Investigational medicinal product code	ATC Code: L01XC10
Other name	Arzerra
Pharmaceutical forms	Solution for solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Ofatumumab was supplied free of charge to study centres by GlaxoSmithKline UK (100mg and 1000mg vials for IV infusion).

Ofatumumab 300mg IV day 1 week 7, 1000mg IV d1 weeks 8-15, 17, 19, 21.

<b>Number of subjects in period 1</b>	Baseline
Started	64
Completed	64

## Period 2

Period 2 title	Induction Therapy
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Induction therapy
------------------	-------------------

**Arm description:**

- Initially the induction treatment regimen included Alemtuzumab instead of Ofatumumab and a subsequent randomisation to lenalidomide maintenance or no further treatment for eligible patients (2 years follow-up). The study was planned to recruit 85 patients but only 16 were recruited before Alemtuzumab was withdrawn. All 16 patients received treatment and were followed-up as per protocol.
- Alemtuzumab was replaced by Ofatumumab; the study was re-initiated with the same design, statistical considerations and recruitment target; 85 more patients were planned to be recruited.
- Recruitment target was reduced to 50 patients resulting in new statistical considerations (increased type I error rate).
- Randomised part of the study was dropped due to very few patients being eligible and follow-up reduced to one instead of two years. This affected only the last two patients recruited in the study.

Arm type	Experimental
Investigational medicinal product name	Alemtuzumab
Investigational medicinal product code	ATC Code: L04AA34
Other name	Campath, MabCampath, Lemtrada
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Prior to its withdrawal, alemtuzumab was sourced commercially by each study centre. Alemtuzumab was administered intravenously in clinic to patients being monitored by research staff.

Alemtuzumab 30mg sc, three times a week, weeks 7-22

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Dexamethasone was sourced commercially by each study centre, biosimilar products were permitted and could be labelled and stored according to local practice.

Dexamethasone 40mg, po, od, days 1-4, weeks 1, 3, 5, 7, 9, 11, 13, 15

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	ATC Code: L04AX04
Other name	Revlimid
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

Lenalidomide was provided free by Celgene for the CLL210 trial in the form of hard capsules of Revlimid; 5mg and 10mg capsules with an excipient of 147mg and 294mg of anhydrous lactose respectively. Stock was ordered from Celgene, via the LCTU using controlled documentation, and delivered direct to site.

Lenalidomide 5mg, od (weeks 3-4), 10mg od (weeks 5-24)

Investigational medicinal product name	Ofatumumab
Investigational medicinal product code	ATC Code: L01XC10
Other name	Arzerra
Pharmaceutical forms	Solution for solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Ofatumumab was supplied free of charge to study centres by GlaxoSmithKline UK (100mg and 1000mg vials for IV infusion).

Ofatumumab 300mg IV day 1 week 7, 1000mg IV d1 weeks 8-15, 17, 19, 21.

<b>Number of subjects in period 2</b>	Induction therapy
Started	64
Completed	35
Not completed	29
Adverse event, serious fatal	6
Change of Diagnosis, and therefore ineligible	1
Physician decision	1

Consent withdrawn by subject	2
Toxicity	4
Adverse event, non-fatal	3
Patient developed ITP at beginning of induction	1
Patient Decision	1
General Condition	1
Reason not known	1
Richters Transformation	1
Disease Progression	7

### Period 3

Period 3 title	Maintenance Therapy
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Maintenance Treatment

Arm description:

Patient receive bi-monthly Lenalidomide for 2 years

Arm type	Experimental
Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	ATC Code: L04AX04
Other name	Revlimid
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

10mg capsules were taken orally, once per day. Patients were dispensed 5mg and 10mg capsules for their own administration, and a drug diary was kept.

<b>Arm title</b>	No Further treatment
------------------	----------------------

Arm description:

Patient do not receive any further treatment, but are followed up for quality of life and survival data

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 3<sup>[1]</sup></b>	Maintenance Treatment	No Further treatment
Started	11	9
Completed	3	9
Not completed	8	0
Physician decision	1	-
Toxicity	1	-
Progressive Disease	4	-
Later elected for transplant, thus in eligible	1	-
New Primary Malignancy (AML)	1	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Responders were eligible for randomisation to maintenance treatment / no further treatment.

## Baseline characteristics

### Reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description: -

Reporting group values	Baseline	Total	
Number of subjects	64	64	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	26	26	
From 65-84 years	37	37	
85 years and over	1	1	
Age continuous			
Units: years			
median	66		
inter-quartile range (Q1-Q3)	59 to 70	-	
Gender categorical			
Units: Subjects			
Female	18	18	
Male	46	46	
WHO Performance status			
Units: Subjects			
PS 0	34	34	
PS 1	24	24	
PS 2	6	6	
Previous Treatment			
Units: Subjects			
No	29	29	
Yes	35	35	
TP53 defect			
Units: Subjects			
No	11	11	
Yes	53	53	
CIRS Total Score			
Units: CIRS Score			
median	2		
inter-quartile range (Q1-Q3)	1 to 4	-	
CIRS Severity Index			
Units: CIRS Index			
median	1		

inter-quartile range (Q1-Q3)	1 to 1.6	-	
------------------------------	----------	---	--

---

## End points

### End points reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description:

Single arm study followed by randomisation to maintenance treatment/no maintenance treatment for responders.

- Initially the induction treatment regimen included Alemtuzumab instead of Ofatumumab and a subsequent randomisation to lenalidomide maintenance or no further treatment for eligible patients (2 years follow-up). The study was planned to recruit 85 patients but only 16 were recruited before Alemtuzumab was withdrawn. All 16 patients received treatment and were followed-up as per protocol.
- Alemtuzumab was replaced by Ofatumumab; the study was re-initiated with the same design, statistical considerations and recruitment target; 85 more patients were planned to be recruited.
- Recruitment target was reduced to 50 patients resulting in new statistical considerations (increased type I error rate).
- Randomised part of the study was dropped due to very few patients being eligible and follow-up reduced to one instead of two years. This affected only the last two patients.

Reporting group title	Induction therapy
-----------------------	-------------------

Reporting group description:

- Initially the induction treatment regimen included Alemtuzumab instead of Ofatumumab and a subsequent randomisation to lenalidomide maintenance or no further treatment for eligible patients (2 years follow-up). The study was planned to recruit 85 patients but only 16 were recruited before Alemtuzumab was withdrawn. All 16 patients received treatment and were followed-up as per protocol.
- Alemtuzumab was replaced by Ofatumumab; the study was re-initiated with the same design, statistical considerations and recruitment target; 85 more patients were planned to be recruited.
- Recruitment target was reduced to 50 patients resulting in new statistical considerations (increased type I error rate).
- Randomised part of the study was dropped due to very few patients being eligible and follow-up reduced to one instead of two years. This affected only the last two patients recruited in the study.

Reporting group title	Maintenance Treatment
-----------------------	-----------------------

Reporting group description:

Patient receive bi-monthly Lenalidomide for 2 years

Reporting group title	No Further treatment
-----------------------	----------------------

Reporting group description:

Patient do not receive any further treatment, but are followed up for quality of life and survival data

Subject analysis set title	Intention to Treat
----------------------------	--------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

All patients recruited into the study

Subject analysis set title	Per Protocol
----------------------------	--------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Patients with a major protocol deviation removed

### Primary: CR/CRi after 6 months of induction therapy

End point title	CR/CRi after 6 months of induction therapy
-----------------	--

End point description:

Number of patients reaching the CR and CRi response criteria following induction therapy.

End point type	Primary
----------------	---------

End point timeframe:

Induction therapy - 6 months

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47 <sup>[1]</sup>	47 <sup>[2]</sup>		
Units: subjects	2	2		

Notes:

[1] - 17 Patients unevaluable

[2] - 17 Patients unevaluable

## Statistical analyses

Statistical analysis title	Complete response rate
Statistical analysis description:	
Estimate of CR/CRI rate with confidence intervals	
Comparison groups	Induction therapy v Intention to Treat
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	other <sup>[3]</sup>
P-value	< 0.158
Method	Clopper-Pearsons exact confidence interc
Parameter estimate	Rate
Point estimate	0.043
Confidence interval	
level	Other: 68.4 %
sides	2-sided
lower limit	0.015
upper limit	0.096

Notes:

[3] - Estimation

## Primary: Toleration of Therapy

End point title	Toleration of Therapy
End point description:	
End point type	Primary
End point timeframe:	
Induction period - 6 months	

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	60 <sup>[4]</sup>	60 <sup>[5]</sup>		
Units: Subjects	27	27		

Notes:

[4] - 4 Unevaluable

[5] - 4 Unevaluable

### Statistical analyses

<b>Statistical analysis title</b>	Toleration of therapy
Comparison groups	Induction therapy v Intention to Treat
Number of subjects included in analysis	120
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.164
Method	Clopper-Pearsons exact confidence interc
Parameter estimate	Rate
Point estimate	0.45
Confidence interval	
level	Other: 67.2 %
sides	2-sided
lower limit	0.38
upper limit	0.521

### Secondary: Partial Response Rate

End point title	Partial Response Rate
End point description:	
Number of patients to achieve PR	
End point type	Secondary
End point timeframe:	
Induction Treatment - 6 months	

<b>End point values</b>	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47 <sup>[6]</sup>	47		
Units: Number of	36	36		

Notes:

[6] - 17 unevaluable

### Statistical analyses

No statistical analyses for this end point

### Secondary: Minimal Residual Disease (MRD) negativity rate following induction therapy

End point title	Minimal Residual Disease (MRD) negativity rate following
-----------------	--

End point description:

The number of patients achieving MRD negativity following complete induction therapy (Measured at WK23 assessment bloods and Bone marrow aspirate).

End point type Secondary

End point timeframe:

Induction Period

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	24	24		
Units: Subjects	6	6		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival (time from start of study treatment to death)

End point title Overall survival (time from start of study treatment to death)

End point description:

2 years OS rate with OS defined as the time from recruitment until death by any cause.

End point type Secondary

End point timeframe:

Duration of the study

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	64	64		
Units: Time (Months)				
number (confidence interval 95%)	.63 (.52 to .77)	.63 (.52 to .77)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-Free survival (time from initiation of study treatment to progression or death)

End point title Progression-Free survival (time from initiation of study treatment to progression or death)

End point description:

2 year PFS rate. PFS defined as the time from recruitment until disease progression or death by any cause

End point type	Secondary
----------------	-----------

End point timeframe:

Duration of Study

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	64	64		
Units: Time (Months)				
number (confidence interval 95%)	.37 (.26 to .53)	.37 (.26 to .53)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to treatment failure

End point title	Time to treatment failure
-----------------	---------------------------

End point description:

2 year TTF rate where TTF is defines as the time from recruitment to treatment failure, disease progression or death by any cause.

End point type	Secondary
----------------	-----------

End point timeframe:

Duration of Study

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	64	64		
Units: Time (Months)				
number (confidence interval 95%)	.33 (.22 to .48)	.33 (.22 to .48)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Response Rate

End point title	Overall Response Rate
-----------------	-----------------------

End point description:

Number of patients to obtain CR/PR

End point type	Secondary
End point timeframe:	
Induction Period - 6 months	

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	47	47		
Units: Subjects	38	38		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Quality of Life

End point title	Quality of Life
End point description:	
Quality of Life measures using the EQ5D QoL form	
End point type	Secondary
End point timeframe:	
During the induction phase of the study	

End point values	Induction therapy	Intention to Treat		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	21	21		
Units: Subjects				
arithmetic mean (standard deviation)	.73 (± .19)	.73 (± .19)		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AE/SAEs were reported from Informed Consent until 28 days after last dose of study treatment (or longer if felt to be a long-term side effect of study treatment). Secondary primary malignancies were reported for the duration of the study.

Adverse event reporting additional description:

Participating centres reported AE / SAE to the LCTU. Centres indicated whether there was a causal relationship in their view between the event and study drugs. A Clinical Coordinator then assessed the event on behalf of the Sponsor.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
Dictionary version	4

### Reporting groups

Reporting group title	Ofatumumab
-----------------------	------------

Reporting group description: -

Reporting group title	Alemtuzumab
-----------------------	-------------

Reporting group description: -

Serious adverse events	Ofatumumab	Alemtuzumab	
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 48 (60.42%)	14 / 16 (87.50%)	
number of deaths (all causes)	19	5	
number of deaths resulting from adverse events	7	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasms benign, malignant, unspec (inc cysts, polyps) - Other			
subjects affected / exposed	3 / 48 (6.25%)	3 / 16 (18.75%)	
occurrences causally related to treatment / all	1 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular disorders			
Visceral arterial ischemia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haematoma			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Thromboembolic event			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
General disorders, admin. site conditions - Other			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnea			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychosis			

subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Creatinine increased			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Blood and lymphatic system disorders			
Anemia			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders - Other			
subjects affected / exposed	0 / 48 (0.00%)	2 / 16 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	3 / 48 (6.25%)	2 / 16 (12.50%)	
occurrences causally related to treatment / all	3 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhea			

subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 48 (0.00%)	2 / 16 (12.50%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Enterocolitis infectious			
subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations - Other			
subjects affected / exposed	1 / 48 (2.08%)	3 / 16 (18.75%)	
occurrences causally related to treatment / all	1 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			

subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	11 / 48 (22.92%)	7 / 16 (43.75%)	
occurrences causally related to treatment / all	5 / 13	4 / 8	
deaths causally related to treatment / all	1 / 2	0 / 0	
Sepsis			
subjects affected / exposed	0 / 48 (0.00%)	5 / 16 (31.25%)	
occurrences causally related to treatment / all	0 / 0	4 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 48 (2.08%)	2 / 16 (12.50%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorectal infection			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis infection			

subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Bronchial infection			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metabolism and nutrition disorders			
Hypercalcemia			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	Ofatumumab	Alemtuzumab	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	48 / 48 (100.00%)	16 / 16 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasms benign, malignant, unspec (inc cysts, polyps) - Other			
subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)	
occurrences (all)	2	2	
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Haematoma			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Hot flashes			

subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)	
occurrences (all)	2	1	
Hypertension			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Hypotension			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Thromboembolic event			
subjects affected / exposed	3 / 48 (6.25%)	1 / 16 (6.25%)	
occurrences (all)	3	1	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	1 / 48 (2.08%)	2 / 16 (12.50%)	
occurrences (all)	1	2	
Edema face			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Edema limbs			
subjects affected / exposed	6 / 48 (12.50%)	8 / 16 (50.00%)	
occurrences (all)	7	13	
Facial pain			
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)	
occurrences (all)	3	0	
Fatigue			
subjects affected / exposed	7 / 48 (14.58%)	5 / 16 (31.25%)	
occurrences (all)	14	9	
Fever			
subjects affected / exposed	7 / 48 (14.58%)	4 / 16 (25.00%)	
occurrences (all)	9	5	
Flu like symptoms			
subjects affected / exposed	4 / 48 (8.33%)	2 / 16 (12.50%)	
occurrences (all)	5	2	
Gait disturbance			

subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
General disorders, admin. site conditions - Other			
subjects affected / exposed	2 / 48 (4.17%)	2 / 16 (12.50%)	
occurrences (all)	4	2	
Infusion related reaction			
subjects affected / exposed	4 / 48 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	5	0	
Localized edema			
subjects affected / exposed	2 / 48 (4.17%)	2 / 16 (12.50%)	
occurrences (all)	2	2	
Malaise			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
Multi-organ failure			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Non-cardiac chest pain			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Pain			
subjects affected / exposed	4 / 48 (8.33%)	1 / 16 (6.25%)	
occurrences (all)	11	1	
Immune system disorders			
Allergic reaction			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	3	0	
Autoimmune disorder			
subjects affected / exposed	0 / 48 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Prostatic obstruction			

subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders - Other			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Atelectasis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Cough			
subjects affected / exposed	9 / 48 (18.75%)	7 / 16 (43.75%)	
occurrences (all)	17	16	
Dyspnea			
subjects affected / exposed	8 / 48 (16.67%)	6 / 16 (37.50%)	
occurrences (all)	12	11	
Epistaxis			
subjects affected / exposed	4 / 48 (8.33%)	3 / 16 (18.75%)	
occurrences (all)	7	5	
Hiccups			
subjects affected / exposed	2 / 48 (4.17%)	2 / 16 (12.50%)	
occurrences (all)	2	4	
Hoarseness			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
Hypoxia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	3	0	
Laryngeal inflammation			
subjects affected / exposed	1 / 48 (2.08%)	2 / 16 (12.50%)	
occurrences (all)	1	3	
Nasal congestion			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Pleural effusion			

subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Postnasal drip			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Productive cough			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
Respiratory failure			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders - Other			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Sore throat			
subjects affected / exposed	1 / 48 (2.08%)	2 / 16 (12.50%)	
occurrences (all)	1	2	
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Anxiety			
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)	
occurrences (all)	4	0	
Confusion			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
Depression			
subjects affected / exposed	4 / 48 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	5	0	
Euphoria			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Insomnia			

subjects affected / exposed	10 / 48 (20.83%)	3 / 16 (18.75%)	
occurrences (all)	10	4	
Mania			
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)	
occurrences (all)	3	0	
Psychiatric disorders - Other, specify			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Psychosis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 48 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	5	0	
Alkaline phosphatase increased			
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)	
occurrences (all)	9	0	
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)	
occurrences (all)	4	0	
Blood bilirubin increased			
subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)	
occurrences (all)	27	7	
Creatinine increased			
subjects affected / exposed	5 / 48 (10.42%)	0 / 16 (0.00%)	
occurrences (all)	14	0	
GGT increased			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	2	1	
Investigations - Other, specify			
subjects affected / exposed	4 / 48 (8.33%)	0 / 16 (0.00%)	
occurrences (all)	9	0	
Neutrophil count decreased			

subjects affected / exposed occurrences (all)	20 / 48 (41.67%) 86	8 / 16 (50.00%) 20	
Platelet count decreased subjects affected / exposed occurrences (all)	11 / 48 (22.92%) 58	7 / 16 (43.75%) 27	
Urine output decreased subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Weight loss subjects affected / exposed occurrences (all)	5 / 48 (10.42%) 5	2 / 16 (12.50%) 2	
White blood cell decreased subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	2 / 16 (12.50%) 29	
Injury, poisoning and procedural complications			
Bruising subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	4 / 16 (25.00%) 4	
Fall subjects affected / exposed occurrences (all)	4 / 48 (8.33%) 5	0 / 16 (0.00%) 0	
Injury, poisoning, procedural complications - Other subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Cardiac disorders			
Acute coronary syndrome subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Palpitations subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 16 (0.00%) 0	
Ventricular fibrillation subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Nervous system disorders			

Concentration impairment		
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)
occurrences (all)	2	0
Depressed level of consciousness		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Dizziness		
subjects affected / exposed	6 / 48 (12.50%)	2 / 16 (12.50%)
occurrences (all)	11	2
Dysarthria		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Dysgeusia		
subjects affected / exposed	2 / 48 (4.17%)	4 / 16 (25.00%)
occurrences (all)	2	4
Headache		
subjects affected / exposed	3 / 48 (6.25%)	3 / 16 (18.75%)
occurrences (all)	5	4
Lethargy		
subjects affected / exposed	7 / 48 (14.58%)	3 / 16 (18.75%)
occurrences (all)	15	5
Neuralgia		
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)
occurrences (all)	2	0
Oculomotor nerve disorder		
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	1
Paresthesia		
subjects affected / exposed	4 / 48 (8.33%)	2 / 16 (12.50%)
occurrences (all)	8	3
Peripheral sensory neuropathy		
subjects affected / exposed	3 / 48 (6.25%)	2 / 16 (12.50%)
occurrences (all)	4	2
Presyncope		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0

Sinus pain			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Somnolence			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Spasticity			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	3	
Stroke			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Tremor			
subjects affected / exposed	0 / 48 (0.00%)	4 / 16 (25.00%)	
occurrences (all)	0	5	
Vasovagal reaction			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anemia			
subjects affected / exposed	12 / 48 (25.00%)	5 / 16 (31.25%)	
occurrences (all)	70	17	
Blood and lymphatic system disorders - Other			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Febrile neutropenia			
subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)	
occurrences (all)	2	1	
Haemolysis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Haemorrhoidal haemorrhage			

subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Leukocytosis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 2	0 / 16 (0.00%) 0	
Lymph node pain subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 4	0 / 16 (0.00%) 0	
Ear and labyrinth disorders Ear and labyrinth disorders - Other subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Hearing impaired subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Tinnitus subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Vertigo subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Eye disorders Blurred vision subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 16 (0.00%) 0	
Eye disorders - Other, specify subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 2	0 / 16 (0.00%) 0	
Optic nerve disorder subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Retinal vascular disorder subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Gastrointestinal disorders			

Abdominal pain		
subjects affected / exposed	2 / 48 (4.17%)	2 / 16 (12.50%)
occurrences (all)	5	2
Anal pain		
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)
occurrences (all)	2	0
Bloating		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Constipation		
subjects affected / exposed	9 / 48 (18.75%)	3 / 16 (18.75%)
occurrences (all)	12	4
Diarrhea		
subjects affected / exposed	15 / 48 (31.25%)	12 / 16 (75.00%)
occurrences (all)	28	24
Dry mouth		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Dyspepsia		
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)
occurrences (all)	5	0
Flatulence		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Gastritis		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Gastroesophageal reflux disease		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Gastrointestinal disorders - Other		
subjects affected / exposed	4 / 48 (8.33%)	2 / 16 (12.50%)
occurrences (all)	5	2
Haemorrhoids		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0

Lower Gastrointestinal hemorrhage subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 16 (6.25%) 1	
Mucositis oral subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 4	4 / 16 (25.00%) 7	
Nausea subjects affected / exposed occurrences (all)	10 / 48 (20.83%) 17	5 / 16 (31.25%) 7	
Oral dysesthesia subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Oral pain subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 16 (0.00%) 0	
Toothache subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Vomiting subjects affected / exposed occurrences (all)	6 / 48 (12.50%) 13	3 / 16 (18.75%) 5	
Hepatobiliary disorders Cholecystitis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	1 / 16 (6.25%) 1	
Dry skin subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	1 / 16 (6.25%) 1	
Hyperhidrosis subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	5 / 16 (31.25%) 8	
Pain of skin			

subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Rash maculo-papular subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 4	4 / 16 (25.00%) 5	
Rash Papular subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Skin and subcutaneous tissue disorders - Other subjects affected / exposed occurrences (all)	7 / 48 (14.58%) 10	6 / 16 (37.50%) 17	
Skin ulceration subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 16 (6.25%) 1	
Urticaria subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	1 / 16 (6.25%) 2	
Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Cystitis noninfective subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Renal and urinary disorders - Other, specify subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Urinary frequency subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	2 / 16 (12.50%) 2	
Urinary retention subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 16 (6.25%) 1	
Urinary tract pain			

subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 3	1 / 16 (6.25%) 1	
Arthritis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 7	1 / 16 (6.25%) 2	
Back pain subjects affected / exposed occurrences (all)	5 / 48 (10.42%) 7	2 / 16 (12.50%) 2	
Bone pain subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Chest wall pain subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 16 (6.25%) 1	
Generalized muscle weakness subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 16 (6.25%) 3	
Joint range of motion decreased subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 16 (0.00%) 0	
Muscle weakness lower limb subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	3 / 16 (18.75%) 4	
Musculoskeletal, connective tissue disorder - Other subjects affected / exposed occurrences (all)	5 / 48 (10.42%) 8	4 / 16 (25.00%) 5	
Myalgia			

subjects affected / exposed	1 / 48 (2.08%)	3 / 16 (18.75%)	
occurrences (all)	1	6	
Neck pain			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
Pain in extremity			
subjects affected / exposed	4 / 48 (8.33%)	1 / 16 (6.25%)	
occurrences (all)	6	3	
Infections and infestations			
Anorectal infection			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Bronchial infection			
subjects affected / exposed	0 / 48 (0.00%)	2 / 16 (12.50%)	
occurrences (all)	0	2	
Encephalitis infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Enterocolitis infectious			
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)	
occurrences (all)	1	0	
Infections and infestations - Other			
subjects affected / exposed	11 / 48 (22.92%)	9 / 16 (56.25%)	
occurrences (all)	19	17	
Lung infection			
subjects affected / exposed	6 / 48 (12.50%)	5 / 16 (31.25%)	
occurrences (all)	7	5	
Mucosal infection			
subjects affected / exposed	1 / 48 (2.08%)	3 / 16 (18.75%)	
occurrences (all)	1	4	
Pharyngitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Rash pustular			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	

Sepsis			
subjects affected / exposed	4 / 48 (8.33%)	7 / 16 (43.75%)	
occurrences (all)	4	9	
Sinusitis			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	1	1	
Skin infection			
subjects affected / exposed	2 / 48 (4.17%)	2 / 16 (12.50%)	
occurrences (all)	3	3	
Tooth infection			
subjects affected / exposed	0 / 48 (0.00%)	1 / 16 (6.25%)	
occurrences (all)	0	1	
Upper respiratory infection			
subjects affected / exposed	15 / 48 (31.25%)	4 / 16 (25.00%)	
occurrences (all)	36	6	
Urinary tract infection			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	5 / 48 (10.42%)	1 / 16 (6.25%)	
occurrences (all)	5	1	
Dehydration			
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)	
occurrences (all)	2	1	
Glucose intolerance			
subjects affected / exposed	2 / 48 (4.17%)	0 / 16 (0.00%)	
occurrences (all)	2	0	
Hypercalcemia			
subjects affected / exposed	3 / 48 (6.25%)	0 / 16 (0.00%)	
occurrences (all)	4	0	
Hyperglycemia			
subjects affected / exposed	3 / 48 (6.25%)	4 / 16 (25.00%)	
occurrences (all)	26	4	
Hyperkalemia			

subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	2	0
Hypermagnesemia		
subjects affected / exposed	1 / 48 (2.08%)	1 / 16 (6.25%)
occurrences (all)	1	1
Hyperuricemia		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0
Hypoalbuminemia		
subjects affected / exposed	3 / 48 (6.25%)	1 / 16 (6.25%)
occurrences (all)	10	1
Hypocalcemia		
subjects affected / exposed	9 / 48 (18.75%)	1 / 16 (6.25%)
occurrences (all)	29	5
Hypoglycemia		
subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)
occurrences (all)	3	1
Hypokalemia		
subjects affected / exposed	7 / 48 (14.58%)	0 / 16 (0.00%)
occurrences (all)	29	0
Hypomagnesemia		
subjects affected / exposed	2 / 48 (4.17%)	1 / 16 (6.25%)
occurrences (all)	2	1
Hyponatremia		
subjects affected / exposed	3 / 48 (6.25%)	1 / 16 (6.25%)
occurrences (all)	8	1
Hypophosphatemia		
subjects affected / exposed	4 / 48 (8.33%)	0 / 16 (0.00%)
occurrences (all)	27	0
Metabolism and nutrition disorders - Other		
subjects affected / exposed	3 / 48 (6.25%)	2 / 16 (12.50%)
occurrences (all)	7	2
Tumor lysis syndrome		
subjects affected / exposed	1 / 48 (2.08%)	0 / 16 (0.00%)
occurrences (all)	1	0



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 March 2011	<p>Changes made following REC and regulatory review of version 1:</p> <ul style="list-style-type: none"><li>o Justification for the use of subcutaneous alemtuzumab added to section 3.2.</li><li>o Alteration to maintenance phase: trial medication (and pharmacovigilance and follow-up) will continue until disease progression or death for any patients that have not progressed by the time of the primary analysis (2.5 years after the last patient has been recruited). It was intended that Revlimid would continue to be made available to those patients off-trial but they remained on-trial until progression. Changes made to sections 2, 8.4 and 10.1.</li></ul> <ul style="list-style-type: none"><li>• Miscellaneous spelling, punctuation and grammar corrections and other minor admin changes.</li></ul>
30 June 2011	<ul style="list-style-type: none"><li>• Changes made to translational research to bring it in line with another CLL trial with sample being collected by the UKCLL biobank<ul style="list-style-type: none"><li>o Section 7.4 updated to include details of collection of and tests to be performed on translational samples collected at baseline</li><li>o Section 9.2.4 updated with details of how bone marrow trephine biopsies are to be processed centrally</li><li>o Section 9.5 updated to emphasise that patients can consent to having baseline and sequential samples taken, or baseline samples only</li></ul></li><li>• Miscellaneous spelling, punctuation and grammar corrections and other minor administrative changes.</li></ul>
26 September 2011	<ul style="list-style-type: none"><li>• Changes made to contact details and list of TSC members.</li><li>• Details of specific tests to be performed at study visits added to section 7.1 and section 9</li><li>• Added details regarding retention of bone marrow trephine samples for future research to section 7.4.</li><li>• Updated links and references to CTCAE v4 (rather than v3 which was used previously)</li><li>• Section 11 (Pharmacovigilance) updated to reflect move to on-line reporting of SAEs and AEs, and annual submission of Development Safety Update Report.</li><li>• Replace QLQ C30 Questionnaire (Appendix E) with CLL210 Health &amp; Quality of Life Questionnaire, and updated references in protocol.</li><li>• Miscellaneous spelling, punctuation and grammar corrections and other minor admin changes.</li></ul>
09 February 2012	<ul style="list-style-type: none"><li>• Section 2 (and 6.2) - Extra qualification on exclusion criterion "Seropositivity for HIV, HCV or HBV (surface antigen and core antibody)" added.</li><li>• Section 8.2.4 (and 8.4.4 and 8.5) - Allow sites to give alternative equivalent co-trimoxazole regimens according to local practice.</li><li>• Section 8.2.4 - Changed days that patient should receive alendronic acid to 70mg on day 1 of weeks 1, 3, 5, 7, 9, 11, 13 and 15 of treatment, on advice from pharmacists.</li><li>• Section 8.4.2 - Changed references from lenalidomide SPC to lenalidomide IB.</li><li>• Miscellaneous spelling, punctuation and grammar corrections and other minor admin changes.</li></ul>

25 November 2012	<ul style="list-style-type: none"> <li>• Changed study title to reflect substitution of alemtuzumab for ofatumumab.</li> <li>• Section 2. Clarified that an estimated 58 patients will be randomised to lenalidomide maintenance versus no further treatment (changed from 54).</li> <li>• Sections 2, 6.1. Qualified inclusion criterion relating to previous treatment episodes for CLL by adding "excluding chlorambucil-based regimen.</li> <li>• Sections 3.1, 3.2. - Rewritten study objectives and rationale and combined into new section.</li> <li>• Section 8 - Major updates to this section to reflect replacement of alemtuzumab with ofatumumab in induction treatment regimen.</li> <li>• Section 10.5.1 - Added futility analysis to stopping guidelines.</li> </ul>
19 September 2013	<ul style="list-style-type: none"> <li>• Update to contact details for Professor Andrew Pettitt and Dr Lukas Smolej</li> <li>• Dr Arvind Arumainathan added as co-investigator</li> <li>• Serum biochemistry assessments chloride, bicarbonate, γGT no longer required. Uric Acid required at baseline only.</li> <li>• Section 8.2.4, 8.4.4 LMW heparin can be given as an alternative to aspirin if patients at high risk of thrombosis.</li> </ul>
27 November 2013	<ul style="list-style-type: none"> <li>• Removed exclusion criterion "Hepatic impairment (serum bilirubin more than twice the upper limit of normal unless due to Gilbert's syndrome)" as already covered by another criterion.</li> <li>• Section 8.2 - Allow local investigators the discretion to extend tapering dexamethasone dose for patients who have steroid withdrawal symptoms, and to allow a tapering dose if patient had grade 3/4 steroid related toxicities prior to starting on study treatment.</li> <li>• Section 8.2.3.1 - Allow lenalidomide to be started and dose increased if low platelet and neutrophil counts are due to underlying CLL.</li> </ul>
04 August 2014	<ul style="list-style-type: none"> <li>• Section 6.1 - Removed the inclusion criterion "No more than 3 previous treatment episodes for CLL (excluding chlorambucil-based regimens)".</li> <li>• Section 9.6 - Added details of Genomics England 10,000 Genomes Project to sub-studies section.</li> </ul>
27 October 2014	<ul style="list-style-type: none"> <li>• Removed references to maintenance part of study from all parts of protocol (including in study title).</li> <li>• Change to protocol to reduce target recruitment from 85 to 50 and remove maintenance part of study. Affects sections 2, 5, 7.3, 8, 10, 12, 14.4.5</li> <li>• Section 2, 6.2. Changes to the wording of the exclusion criterion relating to women of childbearing potential.</li> <li>• Section 8.5 Updates to the pregnancy prevention plan text.</li> <li>• Update to primary endpoints and major changes to section 10 (statistical considerations), as a result of the above changes.</li> <li>• Section 17.3 Change to timing of ISDMC meetings</li> </ul>
07 August 2015	<ul style="list-style-type: none"> <li>• Section 2, 6.2. Reverted final exclusion criterion to state that women of children bearing potential who do are "unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol" are excluded from the study, instead of "study start to 28 days after the last dose of protocol" as in version 10.</li> </ul>

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
------	--------------	--------------

11 September 2012	The Original Protocol of the CLL210 trial used Alexmtuzumab in the induction therapy. Marketing Authorisation for the indication of CLL was withdrawn and so the study suspended recruitment. The Study was then restarted using Ofatumumab instead. The study continued from restart to end of study declaration without any further interruption.	-
-------------------	---	---

Notes:

## Limitations and caveats

None reported